- Home
- -
- Example Page
Example Page
- Opening Hours
Mon – Fri:08:00 am – 20:00 pm
Sun:08:00 am – 12:00 pm
We Socialize
Socialize and Create something special with like-minded people. Nullam at nibh luctus, ultricies ante at, condimentum libero. Fusce hendrerit porttitor tellus nec vestibulum. Praesent vel urna et sem consectetur.


Work With Comfort
Socialize and Create something special with like-minded people. Nullam at nibh luctus, ultricies ante at, condimentum libero. Fusce hendrerit porttitor tellus nec vestibulum. Praesent vel urna et sem consectetur.
why we're the best
About Our Spaces
Lorem ipsum dolor sit amet, sed diam nonumy eirmod tempor invidunt ut labore et.

Trusted
Professional Workspaces
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus,

Innovative
Partnerships
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus,

High
Quality
Equipment
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus,

Bright
& Inclusive Environment
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus,
Why Choose Us

Guaranteed Growth
Lorem ipsum dolor sit amet, consectetur adipisicing elitsed do eiusmod tempor incididunt

Modern Tools
Lorem ipsum dolor sit amet, consectetur adipisicing elitsed do eiusmod tempor incididunt

Expert Advisors
Lorem ipsum dolor sit amet, consectetur adipisicing elitsed do eiusmod tempor incididunt
Our Services
Financial Analysis
We’ll generate a sitemap for your site, submit it to search engine is and track crawler access.
Marketing Plan
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut.
Business Consult
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut.
Expert Team

Chris Marison
Lorem ipsum dolor sit amet, consectetur adipisicing elitsed do eiusmod tempor incididunt

Adam Smith
Lorem ipsum dolor sit amet, consectetur adipisicing elitsed do eiusmod tempor incididunt

Jan Whitfield
Lorem ipsum dolor sit amet, consectetur adipisicing elitsed do eiusmod tempor incididunt
Our Portfolio

Brand A
Financial Business

Brand B
Financial Business

Brand C
Financial Business

Brand D
Financial Business
You don't need t spend your time to spend your profits.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. est laborum.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. est laborum.
Case Studies
Providing Care for The Sickest In Community.
Our doctors include highly qualified male and female practitioners who come from a range of backgrounds and bring a diversity of skills. Our administration and support staff all have exceptional people skills.
- Need Help?
Still not find suitable time for you? Contact directly to Medical Center.
Title
Disruptions of neurological services, its causes and mitigation strategies during COVID-19: a global review
Author
García-Azorín D, Seeher KM, Newton CR et al
Date published
22 May 2021
Author
Guleid FH, Oyando R, Kabia E et al
Date published
06 May 2021
Title
Disruptions of neurological services, its causes and mitigation strategies during COVID-19: a global review
Author
García-Azorín D, Seeher KM, Newton CR et al
Date published
22 May 2021
Title
Disruptions of neurological services, its causes and mitigation strategies during COVID-19: a global review
Author
García-Azorín D, Seeher KM, Newton CR et al
FAQs




- Ask a question?
Didn’t find what you are looking for? Fill the form and we will get back as soon as possible.
1. Hydroxychloroquine for prevention of COVID-19
Swahili Version
Mtafiti mkuu wa hapa nchini ni Dkt Anthony Etyang: barua pepe Aetyang@kemri-wellcome.org Simu +254 722 417507
Kuna manufaa yanayoweza kupatikana ya kupata kinga dhidi ya maambukizi ya kirusi cha korona iwapo dawa itafanya kazi kwa wale walio kwenye kundi la kupata hydroxychloroquine. Wale watakaokuwa kwenye kundi la kulinganisha pia wanaweza kunufaika kutokana na kukingwa ambako si kwa moja kwa moja yaani kupitia kwa kupungua kwa uwezo wa kusambaa kwa maambukizi.
Hatari zinazohusiana na hydroxychloroquine ziko chini sana, kando na utangazaji mbaya ambao hivi karibuni dawa hiyo umeipokea. Mambo ya kiusalama yamejadiliwa sana na wathibiti wa hapa Kenya na wa kimataifa na mbinu kadhaa zimewekwa kuhakikisha usalama wa washiriki wa majaribio haya.
Washiriki watajibu maswali kadhaa kuhusu historia yao ya kimatibabu, wapeane mililita 25 za damu kwa ajili ya vipimo, watumie dawa (tembe) (hydroxychloroquine au kilinganishi) na waweke rekodi ya joto na dalili za matatizo ya kupumua kupitia njia ya simu ya rununu.
Washiriki watatumia dawa za utafiti kwa muda wa siku 90. Wataombwa waje katika kliniki ya utafiti katika siku ya 30, 60 na ya 90, na ziara ya mwisho ifanywe baada ya miezi 5.
Wale watakaotoa ripoti ya dalili za matatizo ya kupumua wakati wa utafiti, sampuli itokanayo na kupangusa ndani ya pua na kooni itachukuliwa kwa ajili ya vipimo vya uwepo wa virusi vya matatizo ya kupumua.
Utafiti unafanywa katika nchi kadhaa huko Asia, Ulaya na Afrika. Tunatumai kusajili wahudumu wa afya wasiozidi 40,000 dunia nzima.
Kwa sasa kuna vituo 4 vya utafiti huu hapa Kenya; Kilifi, Mombasa, Nairobi na Kisumu. Tunalenga kusajili angalau washiriki 800 na wasiozidi 1,600 katika vituo vyote.
Tutasajili wahudumu wa afya ambao wako kwenye hatari zaidi ya kupata maambukizi ya SARS-CoV-2.
Tunafanya utafiti kujua ikiwa dawa ya hydroxychloroquine inaweza kukinga ugonjwa wa kirusi cha korona. Chloroquine, dawa inayofanana na hydroxychloroquine, ilitumika kwingi katika kukinga na kutibu malaria kwa zaidi ya miaka 50 na pia kutibu maumivu ya viungo (rheumatoid arthritis). Watu wamekuwa wakiitumia kwa miaka mingi. Inaonekana kuwa salama sana, na inaweza kufanya kazi dhidi ya kirusi hiki.
Tungependa kujua ikiwa hydroxychloroquine inapunguza dalili kwa wale wanaopata maambukizi ya kirusi cha korona wakati wanaitumia.
Ugonjwa wa virusi vya korona (COVID-19), unaosababishwa na kirusi kinachoitwa SARS-CoV-2, uliripotiwa mara ya kwanza huko Wuhan China Disemba, 2019 na kufikia sasa umeathiri zaidi ya watu milioni 2 duniani na umetangazwa kama janga la dunia nzima na Shirika la Afya Duniani [World Health Organisation (WHO)]
Hakuna dawa ya kukinga au hata chanjo iliyothibitishwa. Kufikia tarehe 22/9/2020, kulikuwa na vifo zaidi ya 500,000 duniani na kati ya hivi 34,077 vilikuwa Afrika. Tuko mbioni kutafuta matibabu mwafaka na njia za kukinga kadri janga linavyokua.
Kuna wasiwasi mkubwa kwamba ugonjwa wa COVID-19 unaweza kulemea/kuharibu mataifa yenye uwezo mdogo wa kutibu na wa kuwatenga wale walioambukizwa, na unaweza kulemea mifumo ya afya ambayo tayari ni dhaifu. Hatari kwa wahudumu wa afya, kama ilivyoonekana na SARS-CoV hapo nyuma, na sasa katika mataifa mengi na COVID-19, inaweza kuwa tishio kubwa kwa shughuli za utoaji wa huduma kwa jumla.
Watu wanaowahudumia wagonjwa wenye maambukizi ya COVID-19 wako katika hatari kubwa zaidi ya maambukizi. Kuna uhitaji wa dharura wa kutambua dawa zinazoweza kukinga usambazaji wa maambukizi lakini pia zinazoweza kukinga makundi yaliyo kwenye hatari zaidi, kama wale wanaofanya kazi kwenye vituo vya afya, kutokana na kupata maambukizi, ili waweze kuendelea kuhudumia wagonjwa na kulinda familia zao.
English Version
The study has been approved by regulatory authorities in Kenya and is expected to start recruitment in October 2020. Participant follow up is expected to be completed by March 2021 and results published shortly thereafter.
The study may show a benefit of using hydroxychloroquine which would save many lives around the world, or alternatively may show hydroxychloroquine prophylaxis is ineffective so trials can move on to evaluate other possible interventions.
There is a potential benefit of direct protection from corona virus infection if the drug works for those who are in the hydroxychloroquine arm. Individuals in the placebo arm may also benefit from indirect protection through decreased ability of the infection to spread.
Risks related to hydroxychloroquine are very low, despite the recent negative publicity that it has received. Safety issues have been discussed extensively with both local and international regulators and several measures have been put in place to ensure safety of trial participants.
Participants will answer some questions about their medical history, provide 25 ml of blood for testing, take study tablets (hydroxychloroquine or placebo) and record temperature and respiratory symptoms via mobile phone.
Participants will take the study tablets for 90 days. They will be requested to come to the study clinic on days 30,60 and 90, plus a final visit being conducted at 5 months.
Those reporting respiratory symptoms during the course of the study will have nasal and throat swabs collected for testing for the presence of respiratory viruses.
The study is being conducted in multiple countries in Asia, Europe and Africa. We hope to recruit up to 40,000 health care workers worldwide.
There are currently four study sites in Kenya; Kilifi, Mombasa, Nairobi, and Kisumu. We aim to recruit a minimum of 800 and a maximum of 1,600 participants across all sites.
We will enroll health care workers who are at high risk of exposure to SARS-CoV-2 infection.
We are conducting a study to find out whether hydroxychloroquine may prevent development of coronavirus illness. Chloroquine, the medicine very similar to hydroxychloroquine, was used very widely for the prevention and treatment of malaria for over 50 years and also to treat rheumatoid arthritis. People have taken it for many years at a time. It is considered very safe, and it may have effects against the virus.
We would also like to find out if hydroxychloroquine lessens the symptoms for those who do get corona virus infection while taking it.
Coronavirus disease (COVID-19), which is caused by the virus known as SARS-CoV-2, was first reported in Wuhan China in December 2019 and has so far affected over 2 million people globally and has been declared a global pandemic by the World Health Organisation (WHO).
There is no proven effective prophylaxis and no vaccine. As of 22 Sept 2020, there are more than 500,000 deaths globally with 34,077 in Africa. We are in a race against time to find effective treatments and preventive measures as the pandemic grows.
There is major concern that COVID-19 could devastate countries with limited capacity for testing and case isolation, and overwhelm their fragile healthcare systems. The high risk to healthcare workers, as seen with SARS-CoV previously, and now in many countries with COVID-19, could be a major threat to healthcare operations overall.
People who look after patients with COVID-19 infections are at increased risk of infection. There is an urgent need to identify drugs which can prevent the spread of infection but also that prevent high-risk groups, like those working in healthcare facilities, from getting the infection, so they can continue to care for patients and protect their families.
2. ChAdOx1 nCOV-19 Vaccine Trial
Swahili Version
English Version
FAQs for ChAdOx1 nCoV-19 Vaccine Trial (Questions brought about by the on-going vaccine roll out by MoH)
Swahili Version
Upeanaji wa chanjo ya COVID-19 wa serikali unalenga makundi ya walengwa kwa mtindo wa awamu. Takwimu zitokanazo na majaribio yanayoendelea zitaendelea kujulisha utekelezaji wa muda mrefu wa chanjo ya COVID-19 hapa Kenya katika awamu zinazofuata.
Mambo kadhaa yamewezesha uharaka wa kupata chanjo za COVID-19; kwanza, kwamba tafiti zimekuwa zikindelea ambazo zimekuwa zikiangazia familia ya virusi vya korona na kuelewa jinsi virusi hivi vinavyofanya kazi. Pili, teknolojia inayotumika kutengeneza chanjo hii (adenoviruses) pia imetathminiwa kwa miaka mingi (zaidi ya miongo 2) kwa magonjwa tofauti kama vile malaria, RVF, MERS, kichaa cha mbwa, chikungunya, TB na mengineyo. Tatu, watafiti na wafadhili wamekuwa radhi kufanya kazi pamoja, kubadilishana habari na teknolijia mpya kama vile ya kutumia vidudu vya adenoviruses kuharakisha utengenezaji wa chanjo. Mwisho, kwa sababu janga hili ni la dunia nzima, maelfu ya watu wamekuwa radhi kushiriki kwenye majaribio, ambayo yamewezesha utoaji kwa uharaka wa takwimu za usalama na utendajikazi ambazo zinahitajika kujulisha uidhinishaji wa dharura wa chanjo hizo. Katika haya yote, usalama wa chanjo ni muhimu; na hivyo basi uhitaji wa majaribio na ufuatiliaji wa jamii zinazopokea chanjo hizo.
Washiriki watatumia dawa za utafiti kwa muda wa siku 90. Wataombwa waje katika kliniki ya utafiti katika siku ya 30, 60 na ya 90, na ziara ya mwisho ifanywe baada ya miezi 5.
Wale watakaotoa ripoti ya dalili za matatizo ya kupumua wakati wa utafiti, sampuli itokanayo na kupangusa ndani ya pua na kooni itachukuliwa kwa ajili ya vipimo vya uwepo wa virusi vya matatizo ya kupumua.
Takwimu kutoka kwa majaribio ya chanjo zinapeanwa kwa wizara ya afya na bodi nyingine za udhibiti hapa Kenya na kimataifa. Takwimu hizi zinasaidia wizara ya afya kufanya maamuzi kuhusu utoaji wa chanjo. Majaribio ya Kenya yanayofanywa na KEMRI Kilifi yanaendelea vizuri na hakuna wasiwasi wowote wa kiusalama.
Kwa sasa kuna vituo 4 vya utafiti huu hapa Kenya; Kilifi, Mombasa, Nairobi na Kisumu. Tunalenga kusajili angalau washiriki 800 na wasiozidi 1,600 katika vituo vyote.
Tutasajili wahudumu wa afya ambao wako kwenye hatari zaidi ya kupata maambukizi ya SARS-CoV-2.
Katika kampeni kubwa za chanjo baada ya kuleta chanjo mpya, ni kawaida kwa makundi ya kitaifa ya kutoa chanjo kuripoti madhara yoyote makali baada ya kupeana chanjo. Hii haimanishi kwamba madhara hayo yanatokana na chanjo yenyewe, lakini ni desturi nzuri kuyachunguza. Pia, madhara makubwa yaliyo nadra yanahitajika yaangaziwe dhidi ya kinga itokanayo na chanjo. Kwa mfano, ikiwa chanjo imeonyesha hatari ya moja kati ya milioni ya madhara makubwa, hii niilinganishwe na kiwango cha juu cha kinga kinachopeanwa dhidi ya ugonjwa mkali wa COVID. Wizara ya afya inasambaza chanjo kulingana na muongozo wa WHO. Habari zaidi zinaweza kupatikana kupitia kiunganishi hiki Link.
Kwa sasa, serikali inapeana chanjo kwa awamu 3 ikilenga asilimia 30 (30%) ya jamii. Awamu ya 1 – wanaofanya kazi muhimu zinazohitaji kutangamana na watu, wanaoainishwa kama wahudumu wa afya (ikijumuisha wahudumu wa afya ya jamii), na waajiriwa wengine wanaotoa huduma muhimu, ambao kazi zao zinawaweka katika hatari kubwa ya kupata COVID-19; Awamu ya 2 – wenye umri wa zaidi ya miaka 50 na wenye hali ya kiafya iliyo sugu; Awamu ya 3 – miaka 18-50 wenye hali ya kiafya iliyo sugu. Makundi haya ya kijamii yalipewa kipaumbele kulingana na upatikanaji wa chanjo na ufadhili kwa sasa. Kutekelezwa kwa awamu hizi kunawezakufanyika kwa wakati mmoja (kulingana na upatikanaji wa chanjo) na serikali inaweza kupanua kwa makundi mengine ya kijamii (ya walengwa) iwapo chanjo zaidi na ufadhili utapatikana.
Kuna manufaa yanayoweza kupatikana ya kupata kinga dhidi ya maambukizi ya kirusi cha korona iwapo dawa itafanya kazi kwa wale walio kwenye kundi la kupata hydroxychloroquine. Wale watakaokuwa kwenye kundi la kulinganisha pia wanaweza kunufaika kutokana na kukingwa ambako si kwa moja kwa moja yaani kupitia kwa kupungua kwa uwezo wa kusambaa kwa maambukizi.
Hatari zinazohusiana na hydroxychloroquine ziko chini sana, kando na utangazaji mbaya ambao hivi karibuni dawa hiyo umeipokea. Mambo ya kiusalama yamejadiliwa sana na wathibiti wa hapa Kenya na wa kimataifa na mbinu kadhaa zimewekwa kuhakikisha usalama wa washiriki wa majaribio haya.
Akina mama wenye uja uzito na wanaonyonyesha hawakujumuishwa kwenye majaribio ya kwanza yaliyofanywa lakini kwa sasa wanajumuishwa katika mpango ya chanjo katika nchi fulani. Kadri majaribio yanavyoendelea na makundi zaidi ya kijamii kujumuishwa katika chanjo, takwimu zitapatikana. Kundi la WHO la kushauri [WHO Strategic Advisory Group of Experts (SAGE)] kuhusu chanjo linapendekeza kupeana chanjo kwa akina mama wanaonyonyesha[1]. Pia, akina mama wenye uja uzito wanaweza tu kufikiriwa ikiwa manufaa yatazidi hatari na kupitia ushauri wa daktari wao. Kupata chanjo ni chaguo la kibinafsi. Ikiwa una nia ya kupata chanjo, unapaswa kwanza kutathmini hatari yako ya kupata maambukizi ya virusi hivi vinavyosababisha COVID-19 na uzungumze na mhudumu wako wa afya.
https://www.ennonline.net/attachments/3816/FAQ_COVID-19-vaccines-and-breastfeeding_10.02.2021.pdf
Jukumu la kufuatilia madhara makubwa ya chanjo ni la wizara ya afya kupitia kwa mpango wa kitaifa ya chanjo [National Vaccine Immunization Programme (NVIP)], ambayo itafuatilia madhara yote makubwa baada ya kupokea chanjo. Bodi ya madawa na sumu [Pharmacy and Poisons Board] ya Kenya, pia inafuatilia upeanaji wa chanjo kupitia ripoti zinazotoka kwa ngazi ya kaunti na kaunti ndogo
English Version
The vaccine has been approved in very many countries across the world and is being rolled out to the general population including those with underlying conditions. As of 7th March 2021, 22,377,255 doses of at least 1 COVID-19 vaccine had been given to UK residents. This would primarily be the Oxford/Astra Zeneca Vaccine and includes individuals with underlying conditions. No safety concerns have been identified in these groups since the vaccine has been rolled out across several countries. In phase 2/3 trials in the UK, South Africa and Brazil 11,636 individuals were recruited including older adults and individuals with a range of underlying conditions (cardiovascular, respiratory and diabetes) and there were no safety concerns identified in these groups.
Pregnant and breastfeeding mothers were not included in the first clinical trials done but are now being included in vaccination programmes by some countries. As clinical trials continue and more population groups are included into vaccination, data will become available. The WHO Strategic Advisory Group of Experts (SAGE) on immunization recommends vaccination for breastfeeding mothers[1]. Additionally, pregnant women can only be considered if the benefits outweigh the risks and upon guidance by their physician. Getting vaccinated is a personal choice. If you are interested in getting vaccinated, you may first want to assess your risk of exposure to getting the virus that causes COVID-19 and talk to your healthcare provider.
https://www.ennonline.net/attachments/3816/FAQ_COVID-19-vaccines-and-breastfeeding_10.02.2021.pdf
In intensive vaccination campaigns following introduction of a new vaccine, it is routine for national immunization teams to report/flag any serious side effects following vaccination. This does not necessarily mean that the side effects are linked to vaccination itself, but it is good practice to investigate them. Additionally, rare side effects need to be balanced against protection from the vaccine. For example, if a vaccine has shown a one in a million risk of serious side effect, this should be compared against the high level of protection the vaccine offers against serious COVID illness. The MoH is rolling out the vaccine based on current WHO guidance. Further information can be seen through this Link.
Author: García-Azorín D, Seeher KM, Newton CR et al
Date Published: 22 May 2021
Author: Guleid FH, Oyando R, Kabia E et al
Date Published: 06 May 2021
Author: Etyang AO, Lucinde R, Karanja H et. al
Date Published: 23 April 2021
Author: Abimbola S, Asthana S, Montenegro C, et al
Date Published: 22 April 2021
Author: Barasa E, Kairu A, Ng'ang'a W, et al
Date Published: 06 Apr 2021
Author: Petersen E, Lucey D, Blumberg L, et al
Date Published: 24 Feb 2021
Author: Agoti CN, Mutunga M, Lambisia AW, et al
Date Published: 03 Feb 2021
Author: Nyadera IN, Onditi F, Obimbo MM, Muchina SK.
Date Published: 05 Mar 2021
Author: Mburu CN, Ojal J, Chebet R, et al
Date Published: 03 Feb 2021
Author: Thorpe J, Ashby S, Hallab A, et al
Date Published: 28 Nov 2020
Author: Jamrozik E, Littler K, Bull S, et al
Date Published: 22 Jan 2021
Author: Petersen E, Lucey D, Blumberg L, Kramer LD, et al
Date Published: 19 Jan 2021
Author: Uyoga S, Adetifa IMO, Karanja HK, et al
Date Published: 11 Nov 2020
Author: Duke T, English M, Carai S, et al
Date Published: 18 May 2020
Author: Barasa EW et al
Date Published: 13 Oct 2020
PUBLISHED RESEARCH MATERIAL | AUTHOR | PUBLISH DATE |
---|---|---|
Disruptions Of Neurological Services,Its Causes And Mitigation Strategies During COVID-19: A Global Review | GARCÍA-AZORÍN D, SEEHER KM, NEWTON CR ET AL | 22 MAY 2021 |
A Bibliometric Analysis Of COVID-19 Research In Africa | GULEID FH, OYANDO R, KABIA E ET AL | 06 MAY 2021 |
Seroprevalence Of Antibodies To SARS-CoV-2 Among Health Care Workers In Kenya | ETYANG AO, LUCINDE R, KARANJA H ET. AL | 23 APRIL 2021 |
Addressing Power Asymmetries In Global Health: Imperatives In The Wake Of The COVID-19 Pandemic | ABIMBOLA S, ASTHANA S, MONTENEGRO C, ET AL | 22 APRIL 2021 |
Examining Unit Costs For COVID-19 Case Management In Kenya. | BARASA E, KAIRU A, NG'ANG'A W, ET AL | 06 APR 2021 |
Answer To Paredes Et Al. Commenting On "COVID-19 Vaccines Under The International Health Regulations - We Must Use The WHO International Certificate Of Vaccination Or Prophylaxis" | PETERSEN E, LUCEY D, BLUMBERG L, ET AL | 24 FEB 2021 |



- Opening Hours
Mon – Fri:08:00 am – 20:00 pm
Sun:08:00 am – 12:00 pm